| NCT04498117 | III | Newly diagnosed BRCA WT and HRD- stage III/IV ovarian cancer following optimal cytoreduction at primary or interval surgery | A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | AZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MI, MN, NE, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WA, WI | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03772028 | III | Newly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgery | Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy | NY | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04095364 | III | Newly diagnosed stage II-IV low grade serous ovarian cancer that is TP53 WT | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WY | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04606914 | II | Newly diagnosed stage III-IV high grade serous FRalpha+ ovarian cancer (neoadjuvant) | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive | AL | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Mirvetuximab soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) | Clinical Trials |
|
|
| NCT02834975 | II | Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant) | Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy | FL | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04082572 | II | Newly diagnosed advanced solid tumors with dMMR or high MSI | Neoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid Cancers | TX | View Drugs | |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03393884 | I/II | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) (Phase II) | A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | AL, CA, FL, MA, MO, NJ, NY, OK, OR, SD, TN, WA, WI | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | GEN-1 | PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC | IL-12 receptor agonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04024878 | I | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence) (neo-adjuvant or adjuvant and maintenance) | NeoVax With Nivolumab in Patients With Ovarian Cancer | MA | View Drugs | |
NeoVax | | Immune response against neoantigens | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04847063 | I | Ovarian cancer with peritoneal disease - expected to undergo complete cytoreduction | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | MD | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | Floxuridine | WR-138720, 5-FUDR | RNA and DNA synthesis inhibitor | | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer | Mitomycin C | Ametycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706 | DNA synthesis inhibitor | Approved in Other Cancers | Oxaliplatin | OHP, Eloxatine, Dacplat, Dacotin, Eloxatin | DNA damaging agent | | Surgery | | | Clinical Trials |
|
|
| NCT03839524 | I | High grade serous ovarian cancer with complete response after surgery and first-line platinum therapy (w/ banked tumor tissue) | A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum. | AZ, FL, MN | View Drugs | View Results |
TG4050 | Modified Vaccinia Ankara (MVA) personalized vaccine, MyVAC | Immune response against neoantigens | Clinical Trials |
|
|
| NCT05145569 | I | Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant) | A Phase 1b, Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer | PA | View Drugs | View Results |
Bintrafusp alfa | MSB0011359C, M7824 | TGFbeta trap and blocks PD-L1 inhibition of T cells | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02659241 | I | Newly diagnosed high grade serous ovarian cancer (neo-adjuvant) | A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer | OR, TX | View Drugs | |
Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | Clinical Trials |
|
|
| NCT04598321 | I | Newly diagnosed stage II-IV, BRCA MUT, mixed epithelial carcinoma, high grade serous or endometrioid ovarian cancer (neo-adjuvant) | BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA) | RI | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT03943173 | I | Newly diagnosed BRCA MUT ovarian cancer (neo-adjuvant) | NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer | TX | View Drugs | View Results |
|
|